Long 博士強調達拉非尼/曲美替尼在Melanoma治療中的長期療效 – 標靶腫瘤學

Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. It inhibits cancer cell proliferation and metastasis by suppressing MEK protein activity and blocking the MAPK signaling pathway.

Vemurafenib is an oral small molecule inhibitor that targets BRAF V600-mutant tumors and has significant anti-tumor efficacy. However, attention should be paid to potential side effects and safety issues during its use.

Bimetinib is an inhibitor of the MEK signaling pathway. Inhibiting MEK activity can block downstream pathways and suppress abnormal activation caused by upstream gene mutations, thereby exerting an anti-tumor effect.

Cobimetinib was first approved for marketing in the United States in 201, and the latest revised version was updated in May 2023.

Cannefenib is a prescription drug approved by the U.S. Food and Drug Administration (FDA) in 2018. It is used for BRAF V600E and BRAF V600K gene mutations that require FDA approval for testing confirmation. It should be used strictly in accordance with your doctor's instructions.

Dabrafenib is a BRAF inhibitor cancer drug, available as a mesylate. On May 29, 2013, the U.S. Food and Drug Administration (FDA) simultaneously approved the marketing applications of dabrafenib and trametinib. Dabrafenib is approved for the treatment of unresectable melanoma (tumors that cannot be surgically removed) and metastatic melanoma (tumors that have spread to other organs) harboring the BRAF V6 Chemicalbook00E mutation, but not for the treatment of wild-type BRAF melanoma. Mekinist is used to treat BRAF V600E or V600...